Get the Stockscreener App
6.53
4.53%
-0.31
After Hours:
6.53
Tango Therapeutics Inc stock is traded at $6.53, with a volume of 1.78M.
It is down -4.53% in the last 24 hours and down -3.40% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$6.84
Open:
$6.9
24h Volume:
1.78M
Relative Volume:
0.89
Market Cap:
$726.53M
Revenue:
$24.30M
Net Income/Loss:
$-145.57M
P/E Ratio:
-4.9098
EPS:
-1.33
Net Cash Flow:
$-149.17M
1W Performance:
-5.91%
1M Performance:
-3.40%
6M Performance:
+231.47%
1Y Performance:
-34.70%
1-Day Range:
$6.51
$6.90
1-Week Range:
$6.25
$7.15
52-Week Range:
$1.03
$10.85
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.53 | 707.62M | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
News impact scoring models applied to Tango Therapeutics Inc.Weekly Investment Recap & Community Supported Trade Ideas - Newser
Institutional scanner results for Tango Therapeutics Inc.July 2025 Closing Moves & Scalable Portfolio Growth Ideas - Newser
Technical analysis overview for Tango Therapeutics Inc. stock2025 Year in Review & Fast Entry High Yield Stock Tips - Newser
Will Tango Therapeutics Inc. continue its uptrendQuarterly Risk Review & Weekly Momentum Stock Picks - Newser
What MACD and RSI say about Tango Therapeutics Inc.July 2025 News Drivers & Reliable Volume Spike Alerts - Newser
Can machine learning forecast Tango Therapeutics Inc. recoveryBuy Signal & Weekly Stock Performance Updates - Newser
Using Python tools to backtest Tango Therapeutics Inc. strategiesWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Applying Wyckoff theory to Tango Therapeutics Inc. stockTrade Risk Summary & Reliable Entry Point Trade Alerts - Newser
Can momentum traders help lift Tango Therapeutics Inc.Quarterly Profit Summary & Fast Momentum Entry Tips - Newser
Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.7% on Insider Selling - MarketBeat
Tools to assess Tango Therapeutics Inc.’s risk profileWeekly Gains Summary & Step-by-Step Swing Trade Plans - Newser
Tango Therapeutics Inc. stock daily chart insightsPortfolio Risk Report & Reliable Entry Point Trade Alerts - Newser
Real time breakdown of Tango Therapeutics Inc. stock performance2025 Growth vs Value & Smart Allocation Stock Reports - Newser
Will earnings trigger a reversal in Tango Therapeutics Inc.Earnings Risk Summary & Smart Investment Allocation Insights - Newser
Can swing trading help recover from Tango Therapeutics Inc. lossesJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Combining machine learning predictions for Tango Therapeutics Inc.Earnings Recap Report & Technical Confirmation Trade Alerts - Newser
Using Ichimoku Cloud for Tango Therapeutics Inc. technicalsEarnings Growth Summary & Free Community Supported Trade Ideas - Newser
How institutional ownership impacts Tango Therapeutics Inc. stockBreakout Watch & Weekly High Return Stock Forecasts - Newser
will tango therapeutics inc. continue its uptrend2025 EndofYear Setup & Stock Portfolio Risk Control - Newser
Visualizing Tango Therapeutics Inc. stock with heatmapsAnalyst Upgrade & Low Drawdown Investment Strategies - Newser
Rock Ventures Iv L.P. Third Sells 642,906 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock - MarketBeat
Nuveen LLC Acquires Shares of 202,183 Tango Therapeutics, Inc. $TNGX - MarketBeat
Will Tango Therapeutics Inc. outperform the marketJuly 2025 Drop Watch & High Return Trade Opportunity Guides - Newser
Tango Therapeutics (NASDAQ:TNGX) Shares Down 6.7% After Insider Selling - Defense World
What data driven models say about Tango Therapeutics Inc.’s futureMarket Sentiment Review & Entry Point Confirmation Signals - Newser
Published on: 2025-09-10 05:20:00 - Newser
Using data tools to time your Tango Therapeutics Inc. exitJuly 2025 Reactions & Daily Profit Focused Screening - Newser
Tango Therapeutics Inc. stock trend forecastBull Run & Technical Pattern Based Signals - Newser
Published on: 2025-09-10 03:39:40 - Newser
Applying big data sentiment scoring on Tango Therapeutics Inc.Quarterly Earnings Summary & Verified Momentum Stock Ideas - Newser
Can Tango Therapeutics Inc. stock recover from recent declineJuly 2025 Fed Impact & Technical Buy Zone Confirmations - Newser
When is the best time to exit Tango Therapeutics Inc.July 2025 Sentiment & Stock Portfolio Risk Management - Newser
Walleye Capital LLC Cuts Stock Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Is Tango Therapeutics Inc. in a long term uptrendJuly 2025 Decliners & Weekly Top Stock Performers List - Lancaster City Council
Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):